1.Anti-vascular dementia effect of Yifei xuanfei jiangzhuo formula by inhibiting mitochondrial fission
Yulan FU ; Wei CHEN ; Guifeng ZHUO ; Xiaomin ZHU ; Yingrui HUANG ; Jinzhi ZHANG ; Fucai YANG ; Ying ZHANG ; Lin WU
China Pharmacy 2025;36(15):1859-1865
OBJECTIVE To investigate the intervention effect and its potential mechanism of Yifei xuanfei jiangzhuo formula by inhibiting mitochondrial fission in a vascular dementia (VaD) model rats. METHODS VaD rat model was established by bilateral common carotid artery ligation. The experimental animals were randomly divided into sham operation group (SHAM), model group (MOD),Yifei xuanfei jiangzhuo formula low-dose group (YFXF-L), Yifei xuanfei jiangzhuo formula high-dose group (YFXF-H), and Donepezil hydrochloride group (positive control), with 9 animals in each group. After 30 days of intervention, the spatial learning memory ability was assessed by Morris water maze experiment; HE staining was used to observe histopathological changes in CA1 area of hippocampus; ELISA was used to detect the levels of serum inflammatory factors [interleukin-1β (IL-1β) and IL-4]; Western blot was used to detect the expressions of heat shock protein 90 (HSP90)/mixed lineage kinase domain-like protein (MLKL)/dynamin-related protein 1 (Drp1) pathway-related proteins, mitochondrial fusion proteins (MFN1, MFN2), and adenosine triphosphate synthase 5A (ATP5A) in hippocampal tissues. The immunohistochemistry was used to detect the level of phosphorylated MLKL (p-MLKL); real-time fluorescence quantitative PCR was adopted to detect mRNA expressions ofHSP90, MFN1, MFN2 and ATP5A. RESULTS Compared with SHAM group, the escape latency of rats in the MOD group was significantly prolonged, the number of crossing the platform was significantly reduced, and the hippocampal tissues showed typical neuronal damage characteristics, the positive expression level of p-MLKL and the serum level of IL-1β significantly increased, while the serum level of IL-4 significantly decreased, the protein and mRNA expression of HSP90, as well as the protein expressions of p-MLKL/MLKL and p-Drp1(Ser616)/Drp1 were all significantly increased in hippocampal tissue, the protein and mRNA expressions of MFN1, MFN2 and ATP5A, and protein expression of p-Drp1(Ser637)/Drp1 were all significantly decreased (P<0.05). After the intervention of Yifei xuanfei jiangzhuo formula, above indicators in each treatment group were all significantly reversed (P<0.05). CONCLUSIONS Yifei xuanfei jiangzhuo formula may alleviate neuronal damage and neuroinflammatory responses in VaD rats by regulating the HSP90/MLKL/Drp1 signaling pathway, inhibiting mitochondrial fission, thereby maintaining mitochondrial dynamic balance and improving mitochondrial function.
2.Extracellular vesicles as biomarkers and drug delivery systems for tumor.
Xue WANG ; Wenjing CHEN ; Wei ZENG ; Kuanhan FENG ; Yu ZHENG ; Ping WANG ; Fucai CHEN ; Wen ZHANG ; Liuqing DI ; Ruoning WANG
Acta Pharmaceutica Sinica B 2025;15(7):3460-3486
Extracellular vesicles (EVs) are crucial for facilitating intercellular communication, promoting cell migration, and orchestrating the immune response. Recently, EVs can diagnose and treat tumors. EVs can be measured as biomarkers to provide information about the type of disease and therapeutic efficacy. Furthermore, EVs with lower immunogenicity and better biocompatibility are natural carriers of chemicals and gene drugs. Herein, we review the molecular composition, biogenesis, and separation methods of EVs. We also highlight the important role of EVs from different origins as biomarkers and drug delivery systems in tumor therapy. Finally, we provide deep insights into how EVs play a role in reversing the immunosuppressive microenvironment.
3.Engineered plant extracellular vesicles: Emerging nanoplatforms for combinational cancer immunotherapy.
Fucai CHEN ; Rongrong BAO ; Wanyi YANG ; Yijing LU ; Jiaxin GUO ; Wenjing CHEN ; Jiale LI ; Kuanhan FENG ; Wen ZHANG ; Liuqing DI ; Liang FENG ; Ruoning WANG
Acta Pharmaceutica Sinica B 2025;15(11):5663-5701
Plant-derived extracellular vesicles (PDEVs), describe a group of nanoparticles released by plants. These particles are characterized by a lipid bilayer structure containing various proteins, lipids, nucleic acids, and unique metabolites. Although the study on PDEVs is relatively new, having only been around for ten years, they have shown promising development prospects in both basic research and clinical transformation areas. Evidence suggests that PDEVs have excellent application prospects in regulating inflammation and treating tumors. Their distinctive, vesicle-mimicking architecture and stellar biocompatibility render them prime candidates for ferrying various anti-cancer agents, including RNA, proteins, and conventional chemotherapy drugs. Increasingly, studies have shown that PDEVs can be engineered as an innovative platform for combination cancer immunotherapy. Consequently, this paper provides an extensive summary of current developments in engineering methods and strategies for PDEVs in cancer treatment and combined cancer immune therapeutics. The essential characteristics of PDEVs, including the biogenesis process and components, as well as their anti-tumor activity and mechanism, are summarized. Finally, the in vivo safety of PDEVs as delivery vectors and the challenges of scale-up production and clinical transformation are discussed.
4.Investigation and Analysis on Teaching Effect of Medical Genetics Experiment in Seven-year Program
Fangjie CHEN ; Chunyi LI ; Xiaoming LI ; Chunlian JIN ; Fucai LI ; Yanyan ZHAO
Chinese Journal of Medical Education Research 2002;0(01):-
Questionnaire was made to investigate teaching effect and further improve teaching quality of medical genetics experiment.The results showed that the refined experimental contents and reasonable teaching methods were vital to the teaching effect.Furthermore,the ability of independent thinking and operating skills should be considerably emphasized.
5.Experience of intrapericardial pneumonectomy for Ⅲ stagelung cancer
Min ZHANG ; Xiaodong CHEN ; Ti DING ; Fucai LIU
Cancer Research and Clinic 2001;0(04):-
Objective To review the surgical experience of intrapericardial pneumonectomy for Ⅲ stage lung cancer. Methods 35 patients with Ⅲ stage lung cancer received intrapericardial pneumonectomy from January 1990 to December 2000. Results None of the patients was operative death. The side effect rate was 34.3 %. 1, 3, and 5 years survival rate were 75.2 %, 35.8 %, 21.3 % respectively. Conclusion Intrapericardial pneumonectomy can increase obiousiy resect rate of Ⅲ stage lung cancer which is a kind of safe and dependable surgical operation. It can prolong the life and improve the quality of life. [

Result Analysis
Print
Save
E-mail